Deputy chief executive of Guy’s and St Thomas’ NHS Foundation Trust Lawrence Tallon speaking at the unveiling of a new MRI scanner last year. After six years at the helm of the Medicines and ...

Anderson is expecting 2025 to be a pivotal year for his turnaround plan – which revolves around the removal of management ...

The FDA has approved the first generic versions of Johnson & Johnson's big-selling anticoagulant Xarelto, which brought in ...

Bluesky’s less formal and more community-driven environment also offers an opportunity for experimentation. Unlike X, where ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

European life sciences venture capital company Sofinnova Partners has raised €1.2 billion ($1.27 billion) in new funding that ...

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique ...

The UK pharma industry has warned that declining access to new medicines in England – down 10% in recent years – will ...

It's the second year in a row that Lilly has used the Oscars as a platform to drive home a message about GLP-1-based obesity ...

The pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of the most recent trends and technologies. One important piece of the puzzle that ...

The first phase 3 trial of the injectable hepcidin mimetic, called VERIFY, has met all its primary and secondary objectives, ...